RU2695228C2 - Прерывистое введение ингибитора mdm2 - Google Patents

Прерывистое введение ингибитора mdm2 Download PDF

Info

Publication number
RU2695228C2
RU2695228C2 RU2017102319A RU2017102319A RU2695228C2 RU 2695228 C2 RU2695228 C2 RU 2695228C2 RU 2017102319 A RU2017102319 A RU 2017102319A RU 2017102319 A RU2017102319 A RU 2017102319A RU 2695228 C2 RU2695228 C2 RU 2695228C2
Authority
RU
Russia
Prior art keywords
mdm2i
cancer
administration
administered
treatment
Prior art date
Application number
RU2017102319A
Other languages
English (en)
Russian (ru)
Other versions
RU2017102319A (ru
RU2017102319A3 (enExample
Inventor
Стефан ФЕРРЕТТИ
Себастьен ЖЕЭ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2695228(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2017102319A publication Critical patent/RU2017102319A/ru
Publication of RU2017102319A3 publication Critical patent/RU2017102319A3/ru
Application granted granted Critical
Publication of RU2695228C2 publication Critical patent/RU2695228C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017102319A 2014-06-26 2015-06-25 Прерывистое введение ингибитора mdm2 RU2695228C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017406P 2014-06-26 2014-06-26
US62/017,406 2014-06-26
PCT/IB2015/054792 WO2015198266A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Publications (3)

Publication Number Publication Date
RU2017102319A RU2017102319A (ru) 2018-07-26
RU2017102319A3 RU2017102319A3 (enExample) 2019-02-12
RU2695228C2 true RU2695228C2 (ru) 2019-07-22

Family

ID=53510950

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017102319A RU2695228C2 (ru) 2014-06-26 2015-06-25 Прерывистое введение ингибитора mdm2

Country Status (18)

Country Link
US (6) US20170196866A1 (enExample)
EP (1) EP3160463B1 (enExample)
JP (1) JP6728072B2 (enExample)
KR (3) KR102462177B1 (enExample)
CN (2) CN115569197A (enExample)
AU (1) AU2015278765B2 (enExample)
BR (1) BR112016029750A2 (enExample)
CA (1) CA2953079C (enExample)
CL (1) CL2016003295A1 (enExample)
ES (1) ES2856210T3 (enExample)
IL (1) IL249138B (enExample)
MX (1) MX2016017075A (enExample)
PH (1) PH12016502556A1 (enExample)
RU (1) RU2695228C2 (enExample)
SG (1) SG11201609853VA (enExample)
TN (1) TN2016000522A1 (enExample)
TW (1) TW201613576A (enExample)
WO (1) WO2015198266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
KR20180058866A (ko) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN109982702A (zh) * 2016-11-15 2019-07-05 诺华股份有限公司 HDM2-p53相互作用抑制剂的剂量及方案
RU2753527C2 (ru) * 2017-03-31 2021-08-17 Новартис Аг ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ
WO2019174576A1 (zh) * 2018-03-12 2019-09-19 罗欣药业(上海)有限公司 咪唑并吡咯酮化合物及其应用
EP3768717A1 (en) 2018-03-20 2021-01-27 Novartis AG Pharmaceutical combinations
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
JP2021525795A (ja) * 2018-05-25 2021-09-27 カルトス セラピューティクス，インコーポレイテッド 骨髄増殖性腫瘍を治療する方法
WO2020128892A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Extended low dose regimens for mdm2 inhibitors
JP2022547311A (ja) 2019-09-16 2022-11-11 ノバルティス アーゲー 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076786A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2012080389A1 (en) * 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
WO2013111105A1 (en) * 2012-01-26 2013-08-01 Novartis Ag Imidazopyrrolidinone compounds
US20130245039A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20140148494A1 (en) * 2010-11-12 2014-05-29 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
CN102770182B (zh) * 2009-12-22 2014-10-29 诺华股份有限公司 被取代的异喹啉酮类和喹唑酮类
PL2361667T3 (pl) 2010-02-25 2015-07-31 General Electric Technology Gmbh Płuczka wodna i sposób oczyszczania gazu procesowego
BR112014003113A2 (pt) 2011-08-11 2017-03-14 Estetra Sprl método de contracepção de emergência em uma fêmea mamífero
EP2793890B1 (en) 2011-12-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
US20150159222A1 (en) 2012-07-31 2015-06-11 Novartis Ag Markers associated with human double minute 2 inhibitors
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EA201690785A1 (ru) 2013-12-05 2016-10-31 Ф. Хоффманн-Ля Рош Аг Новая комбинированная терапия острого миелоидного лейкоза (омл)
US20160331751A1 (en) 2013-12-23 2016-11-17 Novartis Ag Pharmaceutical compositions
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3253387A4 (en) 2015-02-06 2018-12-19 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
CN108348520A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 Mdm2抑制剂和其组合
CN109982702A (zh) 2016-11-15 2019-07-05 诺华股份有限公司 HDM2-p53相互作用抑制剂的剂量及方案
AU2017364332B2 (en) 2016-11-22 2020-07-09 Novartis Ag Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
RU2753527C2 (ru) 2017-03-31 2021-08-17 Новартис Аг ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ
CN111163781B (zh) 2017-10-12 2023-05-16 诺华股份有限公司 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合
EP3768717A1 (en) 2018-03-20 2021-01-27 Novartis AG Pharmaceutical combinations
WO2020092221A1 (en) 2018-10-30 2020-05-07 Dana-Farber Cancer Institute, Inc. Method of treatment of p53 wt tumors
WO2020128892A1 (en) 2018-12-20 2020-06-25 Novartis Ag Extended low dose regimens for mdm2 inhibitors
JP2022525734A (ja) 2019-04-04 2022-05-19 ノバルティス アーゲー シレマドリンスクシナート

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076786A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Substituted isoquinolinones and quinazolinones
US20140148494A1 (en) * 2010-11-12 2014-05-29 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
WO2012080389A1 (en) * 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
WO2013111105A1 (en) * 2012-01-26 2013-08-01 Novartis Ag Imidazopyrrolidinone compounds
US20130245039A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIGGINS B. et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin. Cancer Res. 2014 Jul 15; 20(14): 3742-52. Epub 2014 May 8, , с.3745 1 колонка 1-й абзац. *
HIGGINS B. et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin. Cancer Res. 2014 Jul 15; 20(14): 3742-52. Epub 2014 May 8, реферат, с.3745 1 колонка 1-й абзац. СПРАВОЧНИК. ПРОТИВООПУХОЛЕВАЯ ХИМИОТЕРАПИЯ. Под ред. Переводчиковой Н.И. М.: Медицина, 1993, с.124, раздел Хемодектомы, с.147 2-й абзац - 149. *
СПРАВОЧНИК. ПРОТИВООПУХОЛЕВАЯ ХИМИОТЕРАПИЯ. Под ред. Переводчиковой Н.И. М.: Медицина, 1993, с.124, раздел Хемодектомы, с.147 2-й абзац - 149. *

Also Published As

Publication number Publication date
EP3160463B1 (en) 2020-10-21
RU2017102319A (ru) 2018-07-26
US20210000824A1 (en) 2021-01-07
ES2856210T3 (es) 2021-09-27
KR102462177B1 (ko) 2022-11-04
CA2953079C (en) 2023-05-02
AU2015278765A1 (en) 2017-01-19
AU2015278765B2 (en) 2018-08-16
CN106456635A (zh) 2017-02-22
KR20240110659A (ko) 2024-07-15
TN2016000522A1 (en) 2018-04-04
CA2953079A1 (en) 2015-12-30
EP3160463A1 (en) 2017-05-03
US20180110779A1 (en) 2018-04-26
KR20170017932A (ko) 2017-02-15
IL249138B (en) 2020-09-30
RU2017102319A3 (enExample) 2019-02-12
US20230092181A1 (en) 2023-03-23
PH12016502556A1 (en) 2017-04-17
BR112016029750A2 (pt) 2017-08-22
WO2015198266A1 (en) 2015-12-30
US20190209561A1 (en) 2019-07-11
JP2017519019A (ja) 2017-07-13
US20170196866A1 (en) 2017-07-13
CN115569197A (zh) 2023-01-06
CL2016003295A1 (es) 2017-07-28
KR20220151027A (ko) 2022-11-11
SG11201609853VA (en) 2017-01-27
TW201613576A (en) 2016-04-16
US11419870B2 (en) 2022-08-23
US20220233530A9 (en) 2022-07-28
US20240261284A1 (en) 2024-08-08
JP6728072B2 (ja) 2020-07-22
IL249138A0 (en) 2017-01-31
MX2016017075A (es) 2017-05-03

Similar Documents

Publication Publication Date Title
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
RU2492864C2 (ru) Способ лечения рака, несущего мутации egfr
JP6890659B2 (ja) ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
WO2013049581A1 (en) Compositions and methods for the treatment of proliferative diseases
KR20240112932A (ko) 암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
JP2021509395A (ja) がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
CN113453671A (zh) 用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
CN114246864B (zh) Csf1r激酶抑制剂及其用途
KR20220011651A (ko) Gapdh를 억제하기 위한 방법 및 조성물
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
US20230038138A1 (en) Combination therapy for treating cancer
WO2021175824A1 (en) Method for administration of an anti cancer agent
KR20240164794A (ko) 암 치료를 위한 병용 요법
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
CA2504388A1 (en) Quinazolinone compositions for regulation of gene expression related to pathological processes
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
JP2015528446A (ja) 腎毒性を低減してがんを処置するための改良法
US20080213275A1 (en) Use of mtki 1 for treating or preventing bone cancer
JP2017178960A (ja) 腎毒性を低減してがんを処置するための改良法